AMGN compared with KYTX: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

KYTXKyverna Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

KYTXKyverna Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

AMGNAmgen Inc

479.46▲+0.21%

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

KYTXKyverna Therapeutics, Inc.

5.15▼−0.26%

Regular sessionNov 5 '26

Mkt cap$319.1MRevenue—Revenue—

Compare

Regular sessionNov 5 '26

AMGNAmgen Inc

KYTXKyverna Therapeutics, Inc.

479.46▲+0.21%

Price

5.15▼−0.26%

$258.8B

Mkt cap

$319.1M

Q3 FY26$10.4B

Revenue

—

FY25$36.8B

Revenue

—

AMGN479.46▲+0.21%vsKYTX5.15▼−0.26%Regular sessionNov 5 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

KYTX: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only KYTX 3

—Minaris Advanced Therapiesunlistedsupplier

—National Institutes of Healthunlistedsupplier

—Oxford Biomedica (UK)unlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

AMGN, solidKYTX, dashed